Role of vitamin E-coated membrane in reducing advanced glycation end products in hemodialysis patients: A pilot study

被引:36
作者
Baragetti, I. [1 ]
Furiani, S.
Vettoretti, S.
Raselli, S.
Maggi, F. M.
Galli, F.
Catapano, A. L.
Buccianti, G.
机构
[1] Univ Milan, Dept Med, Div Nephrol & Dialysis, I-20092 Milan, Italy
[2] Univ Milan, Dept Pharmacol Sci, I-20092 Milan, Italy
[3] Univ Perugia, Dept Internal Med, Sect Appl Biochem & Nutr Sci, I-06100 Perugia, Italy
关键词
vitamin E-coated dialyzer; advanced glycation end products; hemodialysis;
D O I
10.1159/000093678
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Advanced glycation end products (AGES) are markers of oxidative stress. Aims: To assess if a vitamin-E-coated dialyzer affects plasma AGE levels and endothelial function in hemodialysis patients. Methods: 16 patients were dialyzed with a synthetic modified cellulose membrane (SMC, n = 8) or a vitamin E-coated dialyzer (n = 8), respectively. At week 32 endothelial function was determined as brachial artery flow-mediated dilatation (FMD). Total AGEs, free pentosidine (FP), protein-bound pentosidine (BP) and autoantibodies against oxidized LDL (ox-LDL-autoantibodies) were assessed at baseline (TO) and at 16, 32, 40 and 42 weeks (T16, T32, T40 and T42). Results: At T16 and T32 FP and BP were lower in vitamin E than in SMC (T 16: 88.7 +/- 8.96 vs. 124.2 +/- 11.90 pmol/ml plasma; p = 0.04, and 22.9 +/- 2.99 vs. 32.8 +/- 2.98 pmol/mg proteins; p = 0.04. T32: 78.7 +/- 8.54 vs. 123.7 +/- 10.15 pmol/ml plasma; p = 0.007, and 19.9 +/- 2.0 vs. 33.67 +/- 2.41 pmol/mg proteins; p = 0.001). In vitamin E, AGEs were lower at T32, T40 and T42 (946.7 +/- 80.91 vs. 1,351.2 +/- 179.33 AU/ml, p = 0.05; 986.9 +/- 59.63 vs. 1,509.9 +/- 154.17 AU/ml, p 0.013; 890.3 +/- 73.70 vs. 1,453.9 +/- 153.16 AU/ml, p 0.009). At T32 AGES, ox-LDL autoantibodies and FMD were inversely correlated (R = -0.70 p = 0.007 and R = -0.59, p = 0.04, respectively). Conclusions: Vit E-coated membrane reduces plasma AGES levels and AGES values are negatively correlated with FMD. Copyright (c) 2006 S. Karger AG, Basel
引用
收藏
页码:369 / 376
页数:8
相关论文
共 35 条
[1]   The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats [J].
Alderson, NL ;
Chachich, ME ;
Youssef, NN ;
Beattie, RJ ;
Nachtigal, M ;
Thorpe, SR ;
Baynes, JW .
KIDNEY INTERNATIONAL, 2003, 63 (06) :2123-2133
[2]   Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans [J].
Anderson, TJ ;
Meredith, IT ;
Charbonneau, F ;
Yeung, AC ;
Frei, B ;
Selwyn, AP ;
Ganz, P .
CIRCULATION, 1996, 93 (09) :1647-1650
[3]   Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial [J].
Boaz, M ;
Smetana, S ;
Weinstein, T ;
Matas, Z ;
Gafter, U ;
Iaina, A ;
Knecht, A ;
Weissgarten, Y ;
Brunner, D ;
Fainaru, M ;
Green, MS .
LANCET, 2000, 356 (9237) :1213-1218
[4]   ADVANCED GLYCOSYLATION PRODUCTS QUENCH NITRIC-OXIDE AND MEDIATE DEFECTIVE ENDOTHELIUM-DEPENDENT VASODILATATION IN EXPERIMENTAL DIABETES [J].
BUCALA, R ;
TRACEY, KJ ;
CERAMI, A .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 87 (02) :432-438
[5]   Potential cardiovascular risk factors in chronic kidney disease:: AGEs, total homocysteine and metabolites, and the C-reactive protein [J].
Busch, M ;
Franke, S ;
Müller, A ;
Wolf, M ;
Gerth, J ;
Ott, U ;
Niwa, T ;
Stein, G .
KIDNEY INTERNATIONAL, 2004, 66 (01) :338-347
[6]   Daily haemodialysis improves indices of protein glycation [J].
Floridi, A ;
Antolini, F ;
Galli, F ;
Fagugli, RM ;
Floridi, E ;
Buoncristiani, U .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2002, 17 (05) :871-878
[7]   Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis [J].
Forbes, JM ;
Yee, LTL ;
Thallas, V ;
Lassila, M ;
Candido, R ;
Jandeleit-Dahm, KA ;
Thomas, MC ;
Burns, WC ;
Deemer, EK ;
Thorpe, SM ;
Cooper, ME ;
Allen, TJ .
DIABETES, 2004, 53 (07) :1813-1823
[8]   ADVANCED GLYCOSYLATION ENDPRODUCT-SPECIFIC RECEPTORS ON HUMAN AND RAT T-LYMPHOCYTES MEDIATE SYNTHESIS OF INTERFERON-GAMMA - ROLE IN TISSUE REMODELING [J].
IMANI, F ;
HORII, Y ;
SUTHANTHIRAN, M ;
SKOLNIK, EY ;
MAKITA, Z ;
SHARMA, V ;
SEHAJPAL, P ;
VLASSARA, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (06) :2165-2172
[9]  
JACKSON P, 1995, CLIN CHEM, V41, P1135
[10]   Improved arterial compliance by a novel advanced glycation end-product crosslink breaker [J].
Kass, DA ;
Shapiro, EP ;
Kawaguchi, M ;
Capriotti, AR ;
Scuteri, A ;
deGroof, RC ;
Lakatta, EG .
CIRCULATION, 2001, 104 (13) :1464-1470